| Bioactivity | TAK-041 is a potent and selective GPR139 agonist with an EC50 of 22 nM. TAK-041 has the potential for the research of negative symptoms associated with schizophrenia[1]. | ||||||||||||
| In Vivo | TAK-041 (0.03-3 mg/kg; P.o.) improves social behavior in BALB/c mice[1]. Animal Model: | ||||||||||||
| Name | TAK-041 | ||||||||||||
| CAS | 1929519-13-0 | ||||||||||||
| Formula | C18H15F3N4O3 | ||||||||||||
| Molar Mass | 392.33 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Reichard HA, et al. Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia [published online ahead of print, 2021 Jul 14]. J Med Chem. 2021;10.1021/acs.jmedchem.1c00820. |
TAK-041
CAS: 1929519-13-0 F: C18H15F3N4O3 W: 392.33
TAK-041 is a potent and selective GPR139 agonist with an EC50 of 22 nM. TAK-041 has the potential for the research of ne
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.